← Leaderboards
Ping Chi
Sloan-Kettering Inst Can Research
$18,562,542
Attributed
$18,562,542
Total exposure
10
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.7M · FY2007–25$5M$3.8M$2.5M$1.3M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,887,208 · 8
FDA$3,675,334 · 2
By mechanism
R01$8,304,635 · 4
U01$3,076,366 · 1
T32$2,697,273 · 1
DP2$2,569,500 · 1
P50$955,279 · 1
K08$847,945 · 1
Top collaborators
No co-investigators on record.
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- Danwei Huangfu$13,557,080
- Anna-Katerina Hadjantonakis$18,599,624
- Craig B Thompson$56,520,903
- Mithat Gonen$8,869,475
- Mengmeng Du$2,352,665
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoResistanceMediatingComplexCellsIn VitroMalignant NeoplasmsGenomicsMolecularTumorInsightMutationPathway InteractionsSignal TransductionResponseNeoplastic CellMutantChromatinGrowthNovel TherapeuticsOncogenicSamplingCell GrowthClinical Investigation
Grant awards (39)
Harnessing double stranded-RNA (dsRNA)-response and anti-tumor effect in PRC2-inactivated cancer$727,224
R01 · FY2025 · CA · contact PI
Understanding and targeting MAPK pathway activation in NF1-deficient malignant peripheral nerve sheath tumor (MPNST)$622,197
U01 · FY2025 · CA · contact PI
Phase II Study of ASTX727 in Patients with PRC2 loss Malignant Peripheral Nerve Sheath Tumor (MPNST)$575,542
R01 · FY2025 · FD · contact PI
Project 1: Molecular Determinants of GIST Pathogenesis$487,464
P50 · FY2025 · CA · contact PI
Clinical Scholars Biomedical Research Training Program$328,619
T32 · FY2025 · CA · contact PI
Harnessing double stranded-RNA (dsRNA)-response and anti-tumor effect in PRC2-inactivated cancer$689,468
R01 · FY2024 · CA · contact PI
Understanding and targeting MAPK pathway activation in NF1-deficient malignant peripheral nerve sheath tumor (MPNST)$598,066
U01 · FY2024 · CA · contact PI
Project 1: Molecular Determinants of GIST Pathogenesis$467,815
P50 · FY2024 · CA · contact PI
Clinical Scholars Biomedical Research Training Program$149,428
T32 · FY2024 · CA · contact PI
Harnessing double stranded-RNA (dsRNA)-response and anti-tumor effect in PRC2-inactivated cancer$745,005
R01 · FY2023 · CA · contact PI
Understanding and targeting MAPK pathway activation in NF1-deficient malignant peripheral nerve sheath tumor (MPNST)$616,953
U01 · FY2023 · CA · contact PI
Phase II Study of ASTX727 in Patients with PRC2 loss Malignant Peripheral Nerve Sheath Tumor (MPNST)$575,542
R01 · FY2023 · FD · contact PI
Clinical Scholars Biomedical Research Training Program$362,617
T32 · FY2023 · CA · contact PI
Understanding and targeting MAPK pathway activation in NF1-deficient malignant peripheral nerve sheath tumor (MPNST)$616,953
U01 · FY2022 · CA · contact PI
Epigenetic mechanisms of transcriptional activation of a novel oncogenic ALK variant in cancer$488,718
R01 · FY2022 · CA · contact PI
Phase II Study of ASTX727 in Patients with PRC2 loss Malignant Peripheral Nerve Sheath Tumor (MPNST)$399,250
R01 · FY2022 · FD · contact PI
Understanding and targeting MAPK pathway activation in NF1-deficient malignant peripheral nerve sheath tumor (MPNST)$622,197
U01 · FY2021 · CA · contact PI
Epigenetic mechanisms of transcriptional activation of a novel oncogenic ALK variant in cancer$498,691
R01 · FY2021 · CA · contact PI
Clinical Scholars Biomedical Research Training Program$406,933
T32 · FY2021 · CA · contact PI
Phase2 trial of MEK162 & imatinib combined therapy in GIST, IND119794(09/20/2013)$500,000
R01 · FY2020 · FD · contact PI
Epigenetic mechanisms of transcriptional activation of a novel oncogenic ALK variant in cancer$498,691
R01 · FY2020 · CA · contact PI
Clinical Scholars Biomedical Research Training Program$384,985
T32 · FY2020 · CA · contact PI
Phase2 trial of MEK162 & imatinib combined therapy in GIST, IND119794(09/20/2013)$125,000
R01 · FY2020 · FD · contact PI
Phase2 trial of MEK162 & imatinib combined therapy in GIST, IND119794(09/20/2013)$500,000
R01 · FY2019 · FD · contact PI
Epigenetic mechanisms of transcriptional activation of a novel oncogenic ALK variant in cancer$483,730
R01 · FY2019 · CA · contact PI
Clinical Scholars Biomedical Research Training Program$367,150
T32 · FY2019 · CA · contact PI
Phase2 trial of MEK162 & imatinib combined therapy in GIST, IND119794(09/20/2013)$500,000
R01 · FY2018 · FD · contact PI
Epigenetic mechanisms of transcriptional activation of a novel oncogenic ALK variant in cancer$497,774
R01 · FY2018 · CA · contact PI
Clinical Scholars Biomedical Research Training Program$394,664
T32 · FY2018 · CA · contact PI
Phase2 trial of MEK162 & imatinib combined therapy in GIST, IND119794(09/20/2013)$500,000
R01 · FY2017 · FD · contact PI
Clinical Scholars Biomedical Research Training Program$302,877
T32 · FY2017 · CA · contact PI
Elucidating the roles of ETV1 in the pathogenesis of GIST$169,589
K08 · FY2015 · CA · contact PI
Elucidating the roles of ETV1 in the pathogenesis of GIST$169,589
K08 · FY2014 · CA · contact PI
Elucidating the roles of ETV1 in the pathogenesis of GIST$169,589
K08 · FY2013 · CA · contact PI
An integrative approach to target lineage-specific oncogenic transcription factor$2,569,500
DP2 · FY2012 · CA · contact PI
Elucidating the roles of ETV1 in the pathogenesis of GIST$169,589
K08 · FY2012 · CA · contact PI
Elucidating the roles of ETV1 in the pathogenesis of GIST$169,589
K08 · FY2011 · CA · contact PI
Elucidating Mechanisms of Histone H2B Dynamic Modification in Mammalian Apoptosis$56,702
F32 · FY2008 · CA · contact PI
Elucidating Mechanisms of Histone H2B Dynamic Modification in Mammalian Apoptosis$54,842
F32 · FY2007 · CA · contact PI